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ABSTRACT 
As the buccal route of administration can avoid the first pass effect, the bioavailability of 
drugs that are metabolized in the liver can be increased through this route. Few studies have been 
conducted using oleic acid as a permeation enhancer in any trans-buccal dosage form. The 
objective of this study was to develop a buccal tablet using two concentrations of oleic acid for a 
model drug (ondanestron) via melt extrusion technology and investigate the effects of oleic acid 
on the physicochemical properties of the tablet. Formulations consisting of the active drug 
(ondansetron hydrochloride), polymers and oleic acid were prepared by extrusion. Bioadhesion 
studies were conducted and results obtained were satisfactory.  Permeation studies demonstrated 
a greater drug permeation in the formulation containing a lower concentration of oleic acid. In 
conclusion, permeation studies exhibited the potential of oleic acid as a buccal permeation 
enhancer and the melt-extrusion technology was successfully employed to formulate buccal 
tablets. Conventional techniques of poloxamer gel preparation have disadvantages such as costly 
equipment’s and scale-up issues. Therefore, the objective of this work was to develop poloxamer 
gels by the extrusion technology. Formulations consisted of poloxamer with ketoprofen (active 
drug). On increasing the poloxamer concentration, a decrease in the drug permeation was obtained. 
Other studies conducted were in-vitro release studies, texture analysis and rheological studies. In 
conclusion, this technology could be successfully employed to develop poloxamer gels by 
overcoming the drawbacks associated with the conventional techniques. However, it is not yet 
widely used for semisolid production. Therefore, the aim of the next project was to combine quality 
by design principles with extrusion to study the effect of the process parameters on cream 
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characteristics. Eight formulations were obtained using a 23-factorial design. Only the temperature 
of zone 2 demonstrated a significant impact on the work of adhesion of the creams. A similar 
permeation profile was obtained with the formulations. Stable cream formulations were also 
obtained as demonstrated by the size distribution graphs. In conclusion, this technology coupled 
with a design of experiments approach can be utilized to investigate how extrusion parameters 
could be modified to develop consistent creams with ideal product characteristics. 
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CHAPTER 1 
 
BIO-ADHESIVE DRUG DELIVERY SYSTEM FOR ENHANCING THE PERMEABILITY 
OF A BCS CLASS III DRUG VIA HOT-MELT EXTRUSION TECHNOLOGY 
1. Introduction 
Although the traditional oral route of drug administration is preferred due to its ease of 
administration and patient compliance, disadvantages such as the hepatic first pass metabolism 
and enzymatic degradation inside the GI tract could prevent the successful delivery of drugs 
through this route. Some of the major enzymes present in the liver such as CYP 3A4 and CYP 
3A5 metabolize several drugs after absorption through the digestive system, thereby allowing only 
a small amount of drug to enter the systemic circulation. Drugs that are administered through the 
oral cavity enter the systemic circulation without any deviations through the internal jugular vein. 
By doing so, the bioavailability of the drugs can be improved as the drugs can bypass the first pass 
metabolism. Moreover, when drugs are delivered through the buccal route, they can also avoid 
degradation by digestive enzymes (Verma et al., 2011; Shojaei, 1998).  
Ondansetron hydrochloride (OND), a selective serotonin 5-HT3 receptor antagonist is 
prescribed to reduce nausea and vomiting that comes with cancer chemotherapy and radiotherapy 
(Cho et al., 2008). Its low permeability can be attributed to the extensive first pass hepatic 
metabolism by the cytochrome P450 enzyme system and therefore it has a poor bioavailability of 
60% (Gwak et al., 2004). The drug having a half-life of 3-5 hours and a small molecular weight 
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 of 365.86 Da makes it a perfect candidate for administration through the buccal route (Kumar et 
al., 2011). 
One of the drawbacks of trans-buccal drug delivery systems is the membrane permeability 
barrier. Some of the solutions proposed include drug derivatives, drug saturated systems, physical 
approaches and chemical penetration enhancers. Of these options, the chemical penetration 
enhancers have been a popular choice for investigators (Nicolazzo et al., 2005). Some of the 
characteristics of a penetration enhancer include a fast absorbing enhancing effect, reversible 
action and the enhancer should be non-toxic and not irritating to the buccal tissues (Aungst, 1994; 
Hassan et al., 2010). Examples of penetration enhancers that can be used include surfactants, bile 
salts, polyols and fatty acids. 
Several studies have been conducted demonstrating the use of oleic acid as a permeation 
enhancer in transdermal drug delivery systems (Maurya and Murthy, 2014; Yamane et al., 1995; 
Gao and Singh, 1998; Aungst et al., 1986; Tanojo et al., 1999). A few studies have also been 
conducted using oleic acid as a buccal permeation enhancer. Morishita et al. (2001) studied the 
effect of the permeation enhancers (oleic acid and other unsaturated fatty acids) on the release of 
the drug as well as the hypoglycemic effect of the drug on rat buccal mucosa (Morishita et al., 
2001). Lee et al. and Birudaraj et al. (2005) studied the combined effect of oleic acid and propylene 
glycol on the permeation of a model peptide and drug respectively (Lee and Kellaway, 2000; 
Birudaraj et al., 2005). To date, there are no known studies conducted that combine oleic acid with 
the poorly permeable OND. Furthermore, no studies have utilized these formulations to produce a 
buccal tablet via hot-melt extrusion. Hot-melt extrusion (HME) technology is defined as the 
process of pumping in raw materials that comprise of the drug, the polymer and the excipients to 
obtain a product of uniform shape when subjected to a rotating screw at high temperatures 
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(Crowley et al., 2007). Over the conventional methods of pharmaceutical manufacturing, HME 
provides better efficiency and short times in obtaining the final product, effective in delivering 
drugs to the patient as well as eliminates the use of solvents. Hence, HME has been recognized as 
a suitable alternative over the conventional methods of manufacturing tablets, films, implants, etc. 
which can be delivered through the oral, transdermal and the trans-mucosal routes (Patil et al., 
2016; Tiwari et al., 2016). The novel aim of this study was to formulate a poorly permeable drug 
(OND) into a buccal tablet comprising of two concentrations of oleic acid via the hot-melt 
extrusion technology and to investigate the effect of the concentration of the fatty acid on the 
physicochemical characteristics of the tablet. 
2. Materials and Methods 
2.1. Materials 
Ondansetron hydrochloride (OND) was purchased from A Chemtek Inc. (Worcester). 
Hydroxypropyl methylcellulose (HPMC E5LV) was purchased from Dow Chemical Company 
(Midland). Polyethylene oxide (PEO, Sentry Polyox N10 LEO NF) was a kind gift from Colorcon 
(North Wales). Microcrystalline cellulose (MCC, Avicel NF) was a gift from FMC Biopolymer 
(Brussels). Guar gum was purchased from Hercules Inc. (Wilmington). Magnesium stearate was a 
gift from Alfa Aesar (Lancashire). Oleic acid was purchased from Fisher Scientific (Fair Lawn). 
The other reagents used in this study were of analytical grade. 
2.2. Hot-Melt Extrusion (HME) 
OND, HPMC and PEO and oleic acid were sieved through US #35 mesh screen and 
blended using a V-shell blender (Maxiblend, Globe Pharma, New Brunswick). The blends were 
processed in a co-rotating twin screw extruder with a modified screw design without an extrusion 
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die (Process 11, Thermo Fisher Scientific, Karlsruhe). The first mixing zone located at the third 
zone consisted of 60° elements that would ensure a uniformly powdered mixture. The second 
mixing zone situated at the sixth zone consisted of 90° elements that would provide a homogenous 
mixing to the blend. The physical blend was manually fed into the extruder and the screw speed 
was set at 50 rpm. The temperature of all the zones were heated to 60°C. Milling of the extrudates 
was performed on a comminuting mill (Fitzpatrick, Model “L1A”, Elmhurst) which were then 
sieved using the US #35 and US #40 sieves. The extrudates retained had particle sizes ranging 
between 300 to 425μm. The retained extrudates were stored in foil-lined polyethylene bags until 
further analysis. 
2.3. Characterization of HME granules 
2.3.1. Differential Scanning Calorimetry (DSC) 
DSC studies were conducted on a PerkinElmer Diamond differential scanning calorimeter 
(DSC) with a Pyris Software. Samples of the pure drug and extrudates were prepared by securely 
fastening 2~4 mg of the material into aluminum pans. The samples were heated from 30~240°C 
at a heating rate of 5°C/min. The DSC studies were conducted under an inert nitrogen atmosphere 
with a flow rate of 20 ml/min. 
2.3.2. X-ray Diffraction (XRD) 
XRD diffraction studies were performed for the pure drug, polymers and extrudates on a 
Bruker D8 Advance (Bruker, Billerica) that has a copper-source and theta-2-theta diffractometer 
furnished with a Lynx-eye position sensitive detector. A voltage of 40 kV and a current of 30 mA 
was selected for the generator. The samples were spread over a silicon sample holder. The scan 
was conducted over a range of 2θ angles from 2° to 35° with a 0.05° step size at 3s per step. 
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2.4. Tablet compression 
The extrudates were mixed with guar gum, MCC and magnesium stearate prior to 
compression. Tablets were punched by a ten-station Piccola classic tablet press (SMI, Lebanon) 
using an 8.0 mm flat round punch and a compression force of 200 kg/cm2. A rotational speed of 
10 rpm (production speed of 6000 tablets/hour) was used. 
2.5. Method of analysis 
Drug content was determined using a HPLC system (Waters, Milford) having a dual λ 
absorbance detector and a Waters C18 (4.6 x 150 mm; 5μm particles) column. The mobile phase 
consisted of methanol and 10mM PBS at pH 7.4 in the ratio of 65:35 (%v/v). A steady flow rate 
of 1ml/min was set with the injection volume at 10μL. The drug was detected at a wavelength of 
306 nm (Hu et al., 2011).  
2.6. Ex-vivo permeation 
Freshly slaughtered porcine mucosa was obtained from domestic pigs (Smokehouse meats, 
Pontotoc) and the excess tissue was cut. Franz diffusion cells (Logan Instruments, Somerset) were 
used to conduct the ex-vivo permeation studies. The mucosa was placed between the receptor and 
the donor compartment and clamped with membrane holders. The receptor compartment consisted 
of 5 ml of PBS at pH 7.4 that simulated systemic conditions and the donor compartment comprised 
of the buccal tablet with PBS at pH 6.6 that imitated the salivary conditions. The cells were 
maintained at 37°C with constant stirring. At predetermined time intervals over a span of 6 hours, 
0.5 ml of the sample was taken from the receptor compartment and replaced with PBS 7.4 of the 
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same volume. The samples withdrawn were then subjected to analysis using the HPLC system 
(Jones et al., 2013).  Each value represents the mean ± S.D. (n=3).   
2.7. In-vitro drug release 
The in-vitro dissolution studies were conducted as per the United States Pharmacopoeia 
XIII rotating paddle method. The dissolution media consisted of 150 ml of PBS at pH 6.6. The 
study was conducted at a temperature of 37°C with a paddle speed of 50 rpm (Kumar et al., 2011). 
At regular time intervals for 6 hours, 1 ml of the sample was withdrawn (and filtered using a 10μm 
filter) and replaced with PBS of the same volume. The samples withdrawn were then analyzed 
through the HPLC system. 
2.8. In-vitro bio-adhesion 
Muco-adhesion experiments were performed on a texture analyzer (Model TA.XT2i, 
Texture Technologies Corp. /Stable Micro Systems) with a 5 kg load cell. The mucosa was placed 
on the base of the analyzer with the membrane facing upwards. The tablet to be tested was attached 
using a double-sided tape to the base of a flat end cylindrical probe fixed to the arm of the texture 
analyzer. A speed of 0.1 mm/sec was used to lower the tablet until it touched the mucosa. For a 
time of 120 seconds, a contact force of 0.5 N was applied. After which the tablet was removed 
from the mucosa at a speed of 5 mm/sec. The tack and work of adhesion for each of the formulation 
was measured (Boyapally et al., 2010). 
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2.9. Tablet swelling index 
Tablets were weighed and placed in 5ml of PBS 6.6. At regular time intervals, the tablets 
were removed, and excess liquid was blotted and reweighed again (Hassan et al., 2009). The 
percentage swelling index was calculated using the following equation: 
Swelling Index (%) = 
W2−W1
W2
∗ 100 
Where, W1 and W2 are the weights of the tablet before placing it in phosphate buffer and at regular 
time intervals respectively. 
2.10.  Surface pH 
Tablets were placed in 5 ml of PBS 6.6 for a period of 2 hours after which the pH of the 
tablets was measured by the pH meter (Mettler Toledo, Columbus) (A Ganem-Quintanar et al., 
1998). 
2.11.  Content assay of drug in extrudates 
Twenty tablets were crushed using a mortar and pestle. An equivalent weight of 200 mg 
was dissolved in methanol. The sample was suitably diluted and then subjected to HPLC analysis. 
2.12.  Evaluation of buccal tablets 
2.12.1.  Weight 
Ten tablets from each formulation were weighed using an electronic balance and the 
average weight was calculated. 
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2.12.2.  Thickness 
The thickness of 10 tablets selected from each formulation were measured using a Vernier 
caliper and the average values were calculated. 
2.12.3.  Hardness 
Three tablets from each formulation were subjected to the hardness tester (Hardness tester, 
Schleuniger) and the mean values were calculated. 
2.12.4.  Friability 
A dual scooping projection Vander Kamp friabilator (Vankel Industries Inc., Chatham) 
was used to conduct the friability test. Twenty tablets each were chosen from the two batches and 
were weighed before placing them in the apparatus. A rotating speed of 25 rpm and a time period 
of 4 minutes was set. The tablets were weighed again, and the % friability loss was calculated 
using the following equation: 
Friability loss (%) =
initial weight − final weight
initial weight
∗ 100 
2.13.  Statistical data analysis 
Levels of statistical significance were assessed using an unpaired t-test between the 
formulations. If the difference (p-value) obtained was less than 0.05, the formulations were 
significantly different. The values obtained were a mean of three readings. 
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3.   Results and Discussion 
3.1. Hot-Melt Extrusion (HME) 
The composition of the buccal tablets and the control tablet is shown in Table 1. HPMC 
and PEO provided the muco-adhesion and swelling to the tablet. Oleic acid was selected as a 
penetration enhancer for the drug. Guar gum was incorporated into the formulation to aid in the 
muco-adhesion as well as in the swelling of the polymers. MCC was selected as a diluent and 
magnesium stearate was used as a lubricant. Process parameters such as the temperature, screw 
speed and screw configuration were optimized based on preliminary studies conducted. The 
modified screw design consisting of two mixing zones (Figure 1) that ensured the breakdown of 
agglomerates if any and to provide a homogenous mixing inside the extruder. The temperature set 
for all the zones was below the degradation temperature of oleic acid (>80°C). The process 
parameters produced a minimum torque (2~3%). 
Table 1.  Composition of the control tablet and the buccal tablets (in percentile). 
Formulation OND HPMC PEO Oleic 
acid 
Guar 
gum 
MCC Magnesium 
stearate 
Control 20 25.9 14.0 - 10 29.9 0.1 
F1 
 
EX1 10 29.9 0.1 
20 12.9 7.0 20 
F2 
 
EX2 10 29.9 0.1 
20 19.4 10.5 10 
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Figure 1.  Modified screw configuration of the twin - screw extruder used in this study. 
3.2. Physicochemical properties of HME granules 
3.2.1.   DSC thermogram 
DSC studies were carried out to determine the compatibility of the drug with the polymers 
and other excipients used (Figure 2). The pure drug gave a melting peak of 186.9°C. Both 
formulations presented a crystalline form of the drug. The extruded formulations reduced the 
melting point of the drug with EX1 exhibiting a larger reduction (165.7°C) than EX2 (175.4°C), 
due to the presence of a higher concentration of oleic acid that acted as a plasticizer. DSC studies 
of the pure polymers were also conducted (data not shown). PEO gave a peak of 68.7°C whereas 
an amorphous form of HPMC was obtained. A second peak (at 44°C for EX1 and 55°C for EX2) 
was also present in the formulations. Additional DSC studies on the formulations without PEO 
were conducted. For these formulations, no peak in the range of 40-70°C were obtained. Therefore, 
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it could be concluded that the second peak obtained for the formulations could be attributed to the 
presence of PEO.  
           
Figure 2. DSC results of pure drug and formulations. 
3.2.2.   X-Ray diffraction 
Figure 3 represents the X-Ray diffraction patterns of the pure drug, pure polymers, EX1 
and EX2. OND is a crystalline drug and exhibited a strong peak at 6°. Both the formulations 
exhibited an identical diffractogram to the drug peak thereby supporting the results obtained from 
the DSC experiments stating that the drug present in the formulations after extrusion were 
crystalline in nature. Strong peaks were present at 19° and 24° for the polymer PEO whereas the 
diffractogram for pure HPMC showed no peaks. 
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Figure 3.  XRD diffractograms for pure drug, polymers and formulations. 
3.3. Ex-vivo permeation studies 
Model animals used for permeation studies include dogs, rabbits and monkeys, however 
pigs are more frequently used as their nonkeratinized oral mucosa closely resembles that to the 
human buccal epithelium. The control which did not have any permeation enhancer permeated 
only 0.009 ± 0.001 mg/cm2. As extremely small amounts of drug were permeated from the control, 
the data is not shown. From Figure 6, F1 having a 20 % oleic acid content permeated 1.4 ± 0.1 
mg/cm2 of drug whereas F2 having a 10 % oleic acid content permeated 1.8 ± 0.1 mg/cm2 of drug. 
Each value represents the mean ± S.D. (n=3).    
The potential of oleic acid to act as a permeation enhancer lies in its cis double bond that 
hinders the formation of well-ordered compact structures and as a result enhances the lipid fluidity. 
In addition, oleic acid also disrupts the polar head group as well as the hydrophobic region of the 
membrane lipids that are present in the human buccal epithelial cells (Boelsma et al., 1996; Tanojo 
et al., 1997). In transdermal drug delivery systems, the mechanism of penetration by oleic acid is 
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still being studied, but it has been proposed that when oleic acid permeates the membrane, it 
perturbs the multi-lamellar structure and therefore gives rise to pathways that are open to 
permeation in these domains. As the concentration of oleic acid increases, a distinct phase is 
created within the stratum corneum lipids and hence can no longer disrupt the endogenous lipid 
domains. Therefore, the amount of drug permeating through the membrane decreases with increase 
in oleic acid concentration (Niazy, 1991; Naik et al., 1995; Larrucea et al., 2001; Mak et al., 1990; 
Ongpipattanakul et al., 1991). This phenomenon of change in functional behavior of oleic acid 
which is dependent on the concentration could be extended to trans-buccal drug delivery system 
as can be seen in Figure 4. The results from the t-test revealed a p-value of 0.054 for the 
formulations. As the p-value obtained was equal to 0.05, the two formulations were not quite 
significantly different for the in-vitro permeation studies. 
 
Figure 4.  Cumulative amount of OND permeated vs.  time from buccal tablets. 
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3.4. In - vitro drug release studies 
The in - vitro dissolution profiles for the formulations are shown in Figure 5.  The release 
profile was enhanced with an increase in oleic acid content. Similar results were observed by Hu 
et al (2005) who attributed their results to oleic acid outer layers that favored lipophilic drugs and 
the release mechanism was explained by matrix erosion or diffusion mechanisms (Hu et al., 2005). 
A higher concentration of oleic acid in F1 exhibited a drug release of 85% as compared to the 57% 
drug release shown in F2. Each value represents the mean ± S.D. (n=3).  This was due to the 
crystalline nature of the drug obtained in the formulations that hindered the release of the drug. 
The incomplete release of the drug could be explained by the concentrations of HPMC and 
PEO used. By increasing the molecular weight of the polymer, the viscosity of the gel formed on 
the tablets increases and therefore slows down the release of the drug. Even though the molecular 
weights of the polymers used were low, by increasing the concentration of the polymers in the 
formulations, the results of the drug release obtained would be like that obtained by using high 
molecular weight polymers at lower concentrations (“DOW TC”, “POLYOX Water-Soluble 
Resins”).  
Kinet software was employed to determine the mechanism of drug release. The drug data 
was analyzed using the zero order, first order, Korsmeyer-Peppas and Higuchi kinetic equations 
and the regression coefficient (R2) values were obtained. The formulations fit best into the 
Korsmeyer-Peppas equation (R2 = 0.997 and n = 0.53 for F1 and 0.994 and n = 0.35 for F2). The 
Korsmeyer-Peppas equation is given by: 
𝑄𝑡
𝑄∞
= 𝐾𝑘𝑝 ∗ 𝑡
𝑛 
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Where, Qt is the drug released in time t, Q∞ is the drug release after an infinite time, Kkp is the 
release constant that consists of the structural and geometrical characteristics of the tablets and n 
is the release exponent that specifies the mechanism of the drug release (Korsmeyer et al., 1983). 
As the release constant obtained for F1 was > 0.5, F1 followed the non-Fickian release mechanism 
(drug release followed a diffusion and a matrix erosion mechanism) and as F2 had a release 
constant < 0.5, F2 followed a Fickian release mechanism (drug release was controlled by a 
diffusion-controlled mechanism) (Patil et al., 2015).  The results from the t-test revealed a p-value 
of 0.0088 for the formulations. As the p-value was less than 0.05, the two formulations were 
statistically significant for the in-vitro drug release studies. 
Figure 5. In - vitro drug release profiles of the formulations. 
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3.5. In - vitro bio - adhesion studies 
Duchene et al., described the general mechanism behind muco - adhesive polymers in three 
stages. A close contact between the muco - adhesive incorporated into the formulation and the 
mucus comprised of the first stage. In the second stage, the muco - adhesive macromolecules swell 
and penetrate inside the mucus leading to a physical entanglement. These macromolecules then 
interact with each other through secondary non-covalent bonds making up the third stage (Duchěne 
et al., 1987).  
With increase in hydration over time, HPMC forms a gel that is strong enough to adhere to 
the surface prolonging the contact time. But its high glass transition temperature (> 200°C) 
decreases its flexibility and therefore the polymer provides moderate muco - adhesivity (Karavas 
et al., 2006). PEO is known to have an extensive and rapid penetration into the substrate due to its 
linear flexible chains that have a high segmental mobility. This penetration gives rise to a close 
contact between the polymer and the substrate and therefore increases the bio adhesion (Prodduturi 
et al., 2007).  
Figure 6 shows a force vs. time plot for both the formulations where area under the curve 
stands for work of adhesion. The peak of detachment obtained for F1 was 27.7 ± 1.2 g and for F2 
was 58.0 ± 1.2 g. The work of adhesion obtained for F1 and F2 were 8.2 ± 2.1 g.sec and 15.8 ± 
1.5 g.sec respectively. Each value represents the mean ± S.D. (n=3).   The peak detachment force 
relies on the hydrogen bonds that are developed between the muco - adhesive polymer and the 
mucosa. Physical entanglement can also be associated with detachment forces as it promotes 
interlocking of chains which are a result of the diffusion between the polymer chains and mucus 
glycoproteins. Increase in swelling of the polymer can lead to an intense physical entanglement 
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thereby resulting in a wider force-time curve and therefore enhancing the work of adhesion 
(Hassan et al., 2009). 
 
Figure 6. Force vs. Distance profile for (A) F1 and (B) F2.  
3.6.  Swelling studies 
Figure 7.  represents the results of the swelling study. Each value represents the mean ± 
S.D. (n=3). Generally, when a buccal tablet encounters the medium (e.g. water or PBS), the 
medium penetrates the polymer matrix and the swollen gel like polymer allows the drug to diffuse 
out. The mechanism in which the drug diffuses out is based on the swelling behavior of the 
polymers involved in the formulation (Langer and Peppas, 1981).  
Upon contact with any bodily fluids, the hydrophilic HPMC matrix hydrates starting from 
its outer boundary and works its way towards the center creating a gel like layer that surrounds the 
drug. The diffusion of the drug through the matrix to the media is based on the thickness of this 
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newly formed layer (Tritt-Goc and Piślewski, 2002). A similar swelling mechanism is also 
observed in PEO (Colombo et al., 2000). Khullar et al. demonstrated that with the addition of guar 
gum, the rate of water uptake into the matrix increases and the gum swells when it absorbs water 
(Khullar et al., 1998). 
 From Figure 7, the formulations showed an increase in the % swelling index for up to 2 
hours. Beyond 2 hours, a decrease in the % swelling index was observed. On prolonged exposure 
to the media, the polymer keeps hydrating until a “disentanglement concentration” is reached. At 
this point, the polymer chains would disentangle and separate themselves from the gel matrix. As 
a result, the polymer then undergoes swelling, dissolution and diffusion from the matrix at the 
same time resulting in the erosion of the polymer (Ju et al., 1995). 
 
Figure 7. Swelling study profiles for the formulations. 
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3.7.  Surface pH 
Surface pH of the buccal dosage forms is measured as an acidic or an alkaline pH would 
cause irritation to the mucosa. The pH obtained for F1 was 6.0 ± 0.1 and that of F2 was 5.6 ± 0.1. 
The pH obtained for the formulations were considered safe as they were in an acceptable salivary 
pH range of 5.5 to 7.0. 
3.8.  Evaluation of buccal tablet 
The punched tablets were evaluated for weight, thickness, friability, hardness and 
uniformity of drug content. The results are presented in Table 2. The weight and thickness variation 
were found to be small in the range of 190.9 to 193.4 mg (F1), 200.08 to 201.08 mg (F2) and 0.13 
to 0.14 mm (F1), 0.12 to 0.13 mm (F2), respectively. The obtained friability loss (0.14% and 0.19% 
for F1 and F2 respectively was less than 1%) which indicated that the tablets possessed an excellent 
mechanical strength that could endure external impacts. The drug content of both the tablets were 
uniform as seen in Table 2 and within the acceptable limits.  
4. Conclusions 
Muco - adhesive buccal HME tablets were successfully developed and evaluated. From the 
ex-vivo permeation studies, both formulations showed a significant permeation of the drug over 
the control indicating the ability of oleic acid to work as a permeation enhancer in trans-buccal 
drug delivery systems. The in-vitro drug release studies in which F1 released 85% of the drug was 
explained by the presence of the crystalline form of the drug after extrusion as well as the 
concentration of the polymers used. Also, no significant increase in the drug release was obtained 
after six hours. The combination of the polymers PEO and HPMC along with the addition of guar 
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gum provided substantial adhesion to the buccal tablets. In conclusion, HME technology could be 
employed to prepare muco adhesive buccal tablets. Moreover, the incorporation of oleic acid as a 
permeation enhancer also significantly enhanced the buccal permeation of ondansetron 
hydrochloride. 
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CHAPTER 2 
DEVELOPMENT OF POLOXAMER GEL FORMULATIONS VIA HOT-MELT EXTRUSION 
TECHNOLOGY 
1. Introduction 
An essential component in topical gels are the gelling agents which when dissolved in a 
media form a three-dimensional network of particles that are responsible for the gel’s viscosity 
and semisolid state. Some of the commonly used gelling agents are cellulose derivatives (methyl 
cellulose, hydroxyl propyl cellulose, etc.), carbomers, poloxamers, carboxy methyl cellulose, etc. 
Poloxamer gels have the potential to be in the liquid state at refrigerated temperatures of 4-5°C 
and convert into a gel at body temperature, thereby retarding the release of the drug from the gel. 
This unique property of the poloxamers is termed as “reverse thermal gelation” and has acquired 
great interest in liquid suppository systems, intramuscular drug delivery systems, ocular drug 
delivery systems, etc. Other properties of a poloxamer gel such as its capacity to take in a higher 
drug load, low toxicity, good solubilizing agent, and its ability to stabilize proteins contribute to 
poloxamer gels being potential drug delivery systems (Gilbert et al., 1987; Dumortier et al., 2006). 
Poloxamer gels are conventionally prepared by either the “hot process” or the “cold 
process”. The method of cold process is generally used for the active ingredients that are thermo 
labile.  The main drawback associated with this method is its long processing time. As dissolving 
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solid poloxamer in cold water, can be difficult, the processing times can vary from several hours 
to days thereby making the cold process method an ineffective method for preparing poloxamer  
gels. The hot method of preparation provides an intimate mixing between the polymer and the 
active ingredient that is poorly soluble in water, therefore solubilizing the poorly soluble active in 
the micelle. Both the methods require costly equipment (large refrigeration units, steam heating 
units, de-aeration equipment, etc.) as well as consume a great deal of energy to maintain the 
temperature and extend the duration of the mixing period (Chang et al., 2013; Schmolka et al., 
1972). Another disadvantage associated with these methods is the scale up process. During the 
scale-up processes, the equal distribution of all the components in the formulation as well as a 
proper balance in the physicochemical properties of the formulation is of utmost importance. On 
a small scale, the polymers can form a homogeneous solution with the media using the 
conventional methods of preparation. On a large scale, it would be difficult to uniformly disperse 
large amounts of the polymer in the media using these methods. Inconsistent addition of the 
polymer and insufficient mixing can therefore lead to poor hydration of the polymer (Garg et al., 
2010).  
Hot-melt extrusion (HME) is defined as the process in which raw materials (polymers, drug 
and other excipients) are pumped into the feeder and subjected to mixing by the rotating screws at 
high temperatures which are then passed through a die to form products (films, granules, cylinders) 
of uniform size and shape (Crowley et al., 2007). The HME process has shown potential to develop 
products for application in the transdermal and topical drug delivery systems (McGinity and 
Repka, 2004; Crowley et al., 2013; Aitken-Nichol, 1996; Repka et al., 2004; Bhagurkar et al., 
2016). Developing poloxamer gel formulations using the HME technology is a relatively short 
process and does not require any additional equipment for the removal of air bubbles or cooling 
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units in comparison to the conventional methods of preparation, thereby making this process a 
cost- efficient process. As the final product obtained is a homogeneous gel that does not have 
visible clumps of poloxamer in it, therefore the need to store the gels at lower temperatures after 
preparation is not required. The agitation provided by the mixing elements results in the de-
aggregation of drug particles suspended in the molten polymer leading to a homogenous dispersion 
or a solid solution or both in the extruded product. This type of mixing on a molecular level could 
be useful in the scale up processes. Some of the other advantages of HME include a high product 
density, no significant downstream equipment, manufacturing dosage forms of API with poor 
compressibility index issues, solvent free technique, etc. (Tiwari et al., 2016). 
As the conventional methods of preparing poloxamer gels have several disadvantages, the 
objective of this novel study was to develop poloxamer gel formulations using the hot-melt 
extrusion technology. Poloxamer gels were also prepared using the conventional method (hot 
process method) (control gels) and the characteristic properties of both the gels were compared. 
Ketoprofen (KTP) is a non-steroidal anti-inflammatory drug which has been prescribed for the 
treatment of rheumatoid arthritis and other similar diseases. KTP when administered through the 
oral route results in upper abdominal pain and ulceration of the gastro-intestinal mucosa thereby 
restricting its oral use. To avoid these adverse effects, KTP can be administered though the 
transdermal/topical route and was hence selected as a model drug for this study (Cho and Choi, 
1998).  
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2. Materials and Methods 
2.1. Materials 
Ketoprofen (KTP) was purchased from Hawkins Pharmaceutical group (Minneapolis, 
USA). Poloxamer 407 (Kolliphor P407) was kindly gifted by BASF (Ludwigshafen, Germany). 
The other reagents used in this grade were of analytical grade. 
2.2. Method of preparation 
2.2.1. Conventional method 
The composition of the control gels (i.e. the gels prepared by the conventional method) is 
shown in Table 2. Poloxamer and the drug were melted using a hot plate set at 97°C with gentle 
stirring. Water was slowly added to the mixture with continuous stirring until a homogenous gel 
was obtained. The formulations were then stored at -4°C to achieve clear formulations (Chi and 
Jun, 1991). 
Table 2. Composition of the extruded and control gel formulations (in percentile). 
 
 
 
2.2.2. Hot-melt extrusion method 
The composition of the extruded gels is shown in Table 2. A mixture of poloxamer and 
KTP were sieved through US# 35 mesh screen and blended using a V-shell blender (Maxiblend, 
Poloxamer 407 Water Drug 
30 68 2 
40 57 3 
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Globe Pharma). The mixture was fed through a volumetric feeder into a co-rotating twin screw 
extruder having an extrusion die of diameter 5.79 mm (Process 11, Thermo Fisher Scientific, 
Karlsruhe). Water was added into the extruder through an injection port with the aid of a peristaltic 
pump at zone 5. Figure 8 represents a schematic representation of the extrusion process. The 
temperatures from zones 2-4 were set at 97 °C, zone 5 at 90 °C, zones 6 and 7 at 80 °C and zone 
8 and the die were set to 70 °C. Screw speed of 50 rpm was set. The pump speed was set to 0.83 
rpm and the feeder speed was set to 3 rpm based upon the preliminary studies conducted. A 
modified screw design was used for extrusion that consisted of two mixing zones situated in zones 
3 and 6 respectively as shown in Figure 9. 
 
  Figure 8. Schematic representation of the hot-melt extrusion process of the gel formulations. 
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Figure 9. Modified screw configuration. 
2.3. Characterization of gel formulations 
2.3.1. Differential Scanning Calorimetry (DSC) 
Pure drug, pure poloxamer, blank gel formulations (i.e. the gel formulations that did not 
contain any KTP) and drug loaded gel formulations were physically characterized using the Perkin 
Elmer Diamond DSC equipped with a Pyris software. Each of the samples were weighed and 
hermetically sealed into aluminum pans. The temperature range for the samples was from 30°C to 
200°C at a heating rate of 10°C/min. The DSC studies were performed under an inert nitrogen 
atmosphere having a flow rate of 20 ml/min. 
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2.3.2. X-ray Diffraction (XRD) 
XRD diffractograms were obtained for the pure drug, pure polymer, drug loaded and blank 
gel formulations. These studies were conducted on a Rigaku Miniflex600 (Rigaku Americas, The 
Woodlands) equipped with a Cu-Kα radiation source (and theta-2-theta diffractometer along with 
a Lynx-eye position sensitive detector) with a current of 15mA and a voltage of 40kV for the 
generator. A Si sample holder was used to spread the samples. The powder samples were scanned 
over a range of 5° to 33° 2θ with a 0.05 step size at 1°/min. The gel samples were scanned over a 
range of 5° to 33° 2θ with a step size of 0.02 at 2°/min. 
2.4. Method of analysis 
KTP content was determined using a Waters HPLC UV (Waters Corp, Milford) system 
equipped with a dual λ absorbance detector. A Waters C18 (4.6 x 150 mm; 5 μm particles) column 
was used. The mobile phase comprised of 20 mM phosphate buffer solution (pH 4.5) and 
acetonitrile in the ratio of 60:40 (%v/v). A 1ml/min flowrate and injection volume at 10 μL was 
set. The UV detector was set to 256nm for KTP detection (Ashour et al., 2016). 
2.5. pH measurement 
The gel formulations were first converted into the liquid form by storing them at -4°C. pH 
of the solutions was then measured using the Mettler Toledo InLab® Micro pH probe (Mettler 
Toledo, Columbus) (Chi and Jun, 1991). 
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2.6. Uniformity of drug content 
Accurately weighed amount of gel formulations were taken from different regions of the 
container and dissolved in suitable amounts of acetonitrile and sonicated. The samples were then 
analyzed by HPLC to determine the drug content. 
2.7. Texture analysis 
The texture analysis for the formulations were conducted on a texture analyzer (Model 
TA.XT2i, Texture Technologies Corp. /Stable Micro Systems) using a 5 kg load cell. An acrylic 
cylindrical probe of 1-inch diameter (TA-3) and a soft matter kit (TA-275) were used. The gel was 
applied onto the soft matter fixture with the cylindrical probe attached to the arm of the texture 
analyzer. The surface of the sample was leveled before starting the experiment. The probe was 
lowered at a speed of 0.50 mm/sec till it touched the surface of the sample. On touching the surface 
of the sample and identifying a trigger force of 2.0 g, the probe produced a deformation of up to 
1mm of the sample moving at a speed of 0.50 mm/sec. The probe was then removed from the 
sample at a speed of 5.0 mm/sec. Before the next sample was applied onto the soft matter fixture, 
the base of the probe was cleaned thoroughly (Tai et al., 2014). 
2.8. Rheological characterization 
The rheological analysis for the formulations were conducted on a TA instrument DHR-2 
rheometer. The study was conducted at 32°C and was controlled using a Peltier system. A parallel 
plate geometry (25 mm) was used and adhesive backed sand papers (grit number # 600, Allied 
High-Tech Products) were attached to both upper and lower plates to reduce the sample slippage 
at the sample-rheometer plate interface. 400 mg of the sample was applied onto the lower plate 
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and the upper plate was set to a gap of 550μm. The gap was finally set at 500μm after the excess 
sample was removed. A solvent trap was attached to the rheometer to minimize the water loss from 
the formulations that could occur during the testing. The study was performed in four steps. Firstly, 
a time sweep was done for 5 minutes to let the sample relax from the stress it acquired during 
loading (at strain (γ0) of 0.1% and frequency (ω) of 1 Hz). After the time sweep, the strain sweep 
test was conducted (γ0=0.05–50%, ω=1Hz). The time sweep test was conducted again before the 
steady shear test was performed in the forward and the backward mode. In the forward mode, the 
shear rate was gradually increased to the maximum shear rate (100 s-1) and in the backward 
direction, the shear rate was then decreased to the lowest shear-rate (0.001 s-1) (Bhagurkar et al., 
2016). 
2.9. In - vitro release study 
Vertical Franz diffusion cells with an active diffusion area of 0.64 cm2 (Logan Instruments, 
Somerset) were used to conduct the in - vitro release study. A non-porous hydrophobic silicone 
membrane of thickness 0.005 inches (Speciality Manufacturing, Inc., Saginaw) was used. Gel 
formulations weighing 100 mg were applied onto the membrane and was sandwiched between the 
donor and the receptor compartments. The receptor compartment consisted of phosphate buffer 
saline solution of pH 7.4 that simulated systemic conditions and was degassed before the 
experiment. A temperature of 32°C and constant stirring was provided to the cells. The cells were 
equilibrated for an hour prior to the study. At regular time intervals till the 10th hour, 0.2 ml of the 
samples were withdrawn and replaced with the same volume of PBS. The samples were then 
analyzed using the HPLC (Ueda et al., 2009). 
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2.10. Ex - vivo permeation study 
The ex - vivo permeation studies were conducted on vertical Franz diffusion cells having a 
diffusion area of 0.64 cm2 (Logan Instruments, Somerset). Freshly slaughtered porcine epidermis 
procured from domestic pigs from a local abattoir, were utilized for this study. The epidermis was 
stored in 8°C till further use. On the day of the experiment it was thawed at room temperature. Gel 
formulations weighing 20mg were evenly spread onto the epidermis and clamped between the 
donor and the receptor compartments. 5 ml of PBS at pH 7.4 was used as a receptor media and 
degassed prior to the experiment. The cells were maintained at 32°C with constant stirring. The 
system was kept for equilibration for an hour before the experiment. At predetermined time 
intervals till the 10th hour, 0.2ml of the sample was withdrawn from the cells and replaced with 
fresh PBS of the same volume. The samples were then subjected to analysis by the HPLC (Şenyiğit 
et al., 2011). 
2.11. Extraction of KTP from the epidermis 
At the end of the ex - vivo permeation study, the epidermis was washed several times with 
methanol and water. The active diffusion area was then removed using a biopsy punch and 
weighed. The epidermis was homogenized by adding appropriate amounts of NaOH (2N) to the 
epidermis and storing it at 50°C. Suitable dilutions were made with acetonitrile followed by 
vortexing and centrifuging the solutions. The supernatant was then analyzed for the drug content 
in the epidermis using HPLC (Maurya and Murthy, 2014). 
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2.12. Microscopic studies 
A thin film of the gel formulations (40%) was uniformly spread over a 1 cm2 area on a 
microscopic slide to detect the presence of KTP crystals. The formulations were scanned under a 
microscope at predetermined time intervals till the 2nd hour with a 40x objective lens. Images were 
taken using a Zeiss, Axio Cam ICC1, Lab.A1 camera. 
2.13. Statistical data analysis 
The levels of statistical significance between formulations were evaluated using an 
unpaired t-test. The formulations were significantly different if the p-value obtained was less than 
0.5. A mean of three readings was considered. 
3. Results and Discussion 
3.1. Methods of Preparation 
The formulations were first conventionally prepared using different concentrations of 
poloxamer. The composition of poloxamer gel formulations constituted of 30%, 68%, 2% and 
40%, 57% and 3% poloxamer, water and drug respectively. The control formulations eventually 
formed clear gels after refrigerating the poloxamer solutions for several days. Poloxamer gel 
formulations were also developed through the hot-melt extrusion method and the final product 
obtained were transparent gels devoid of air bubbles. Extrusion parameters such as screw speed, 
screw configuration, zone of water addition as well as feeding rate of the physical blend were 
optimized to provide minimum shear and torque. The first mixing zone consisted of 60° elements 
and was situated at zone three to break down agglomerates of the physical blend if any. The second 
mixing zone consisted of 90° elements and was situated at zone six to ensure that water and the 
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binary mixture were uniformly mixed. In this way, a distributive and a dispersive mixing could be 
provided to the formulations. The temperature of zones 2-4 were set to 97°C to ensure gradually 
decreased to result in the final formulations. The water content of the extruded and the control gel 
formulations were determined through Thermogravimetric Analysis studies (TGA). The results of 
the studies indicated that the extruded and the control gel formulations contained the same amount 
of water (data not shown). 
3.2. Physicochemical Characterization of the Formulations and the Raw Materials 
3.2.1. DSC Thermogram 
DSC studies were conducted to determine the compatibility between the drug and the 
polymer involved. DSC thermograms of the formulations, pure drug and polymer are shown in 
Figure 10. Pure KTP showed a sharp melting peak at 97.2°C. Pure poloxamer also exhibited a 
melting peak at 58.2°C indicating a crystalline nature of the polymer. DSC studies were also 
conducted for the blank (i.e. gel formulation that did not contain any KTP, data not shown) and 
drug loaded gel formulations.  
The results for the blank gel formulation indicated a single endothermic peak in the 
temperature range of 100-110°C. This peak could be attributed to the loss of water in the 
formulations that takes place during the heating cycle of the DSC study. To confirm this 
hypothesis, DSC studies of the blank gel formulations were also conducted in hermetically sealed 
aluminum pinhole pans wherein a similar endothermic peak was observed.  
Two peaks were observed in the drug loaded formulations. The first peak obtained was in 
the temperature range of 50-70°C which could be attributed to the presence of poloxamer. The 
second peak obtained for the formulations was in the same temperature range as the peak obtained 
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for the blank gel formulation. The absence of drug peak in the formulations indicated that the 
crystalline drug had either converted to an amorphous form or was present in the soluble form in 
the polymer matrix after preparation. Solubility studies of the drug in pure poloxamer were 
conducted to determine the nature of the drug after preparation. The drug load and the poloxamer 
content in the formulation was 2% and 30% respectively. From the solubility studies, it was 
determined that the solubility of KTP in poloxamer was much higher (0.37 mg/mg) than the drug 
load in the formulation and therefore all the KTP incorporated existed in a soluble form in the 
polymer matrix. 
      
Figure 10. DSC thermograms of pure drug, polymer and gel formulations. 
3.2.2. X-Ray diffraction 
X-Ray diffraction studies were conducted for pure drug, polymer, blank gel formulation 
and drug loaded gel formulations. The results of the XRD studies are shown in Figure 11. KTP 
was in the crystalline form which was indicated by the presence of strong peaks observed at 2θ 
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19° and 23°. Strong crystalline peaks were also observed for pure poloxamer at 2θ 18°and 23°. 
The blank gel (data not shown) and the drug loaded gel formulations showed no peak 
corresponding to KTP indicating the absence of drug after the gel preparation. The results of the 
XRD studies performed therefore supported the results obtained in the DSC studies. 
          
Figure 11. XRD diffractograms of pure drug, polymer and gel formulations. 
3.3. Texture analysis study 
A texture analysis study investigates the textural characteristics of gel formulations (such 
as its hardness, consistency, work of adhesion, etc.) through which additional information about 
the properties of the gel such as its spreadability, viscosity, muco adhesion, strength, etc. can be 
determined. The force vs. distance profile for the 30% poloxamer formulations is shown in Figure 
12. Firmness or hardness refers to the amount of work required to remove the gel from the 
container and apply it to the desired site. With respect to the force vs. distance profile, it is defined 
as the maximum peak force obtained during the compression cycle (Gilbert et al., 1986).  
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From Figure 12, the firmness obtained for the extruded formulation was 75.3 ± 11.6 g and 
for the control formulation was 83.9 ± 6.8 g. Firmness is directly proportional to the consistency 
of the sample which is indicated by the negative region of the graph. The consistency obtained for 
the extruded formulations is 35.6 ± 8.6 g.sec and for the control formulations is 45.0 ± 2.8 g.sec. 
The work of adhesion (WOA) refers to the spreadability of the gels and from the figure, it is 
indicated by the ratio of the area under the second curve (AUC2) to the area under the first curve 
(AUC1). WOA obtained for the extruded formulations was 96.4 ± 22.8 g.sec and for the control 
formulations was 66.1 ± 8.3 g.sec. The firmness, consistency and WOA results represent the mean 
(n=3). The p-value obtained from the t test for the formulations were as follows – 0.56 for the 
firmness, 0.14 for the consistency and 0.09 for the work of adhesion. Therefore, it could be 
concluded that as the p-values obtained were > 0.05, the formulations were not statistically 
significant for the texture analysis study and thus had similar textural properties (Ricci et al., 2005). 
              
 
Figure 12. Force vs. distance profile for (A) Extruded gel and (B) Control gel. 
A. B. 
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3.4. Rheology study 
The rheology of semi-solid products relies on the product’s microstructure that could be 
affected by process conditions. Therefore, it is important to conduct a rheology study to investigate 
the effects of processing conditions on the rheological properties such as viscoelastic behavior, 
yield stress and the effect of shear rate on the product’s viscosity.  
Figures 13 and 14 A. (extruded and control gels respectively) depict the plot of storage 
modulus (G’) and loss modulus (G”) against strain where G’ represents the elasticity of the product 
and G’’ represents the viscous behavior of the product. As can be seen from the figures, G’ of the 
formulations continued to remain constant up to 1% strain (approximately), after which a decrease 
in G’ was observed. The region in which the G’ remains constant with increase in strain is termed 
as linear viscoelastic region in which the product can recover quickly upon any disturbance. From 
the figures, it can also be observed that G’ is significantly higher than G’’. This indicates that the 
microstructure of the semi-solid product is organized and is controlled by the cohesive forces. Till 
the strain of 1%, the product behaves like a solid. On further increasing the strain, both G’ and G’’ 
decrease wherein G’’ exceeds G’ and the product now behaves like a liquid (Krishnaiah et al., 
2014).  
Yield stress is defined as the stress that is needed to initiate the flow in a product and 
corresponds to changes to the microstructure of the products. In the Figures 13 and 14 B., a plot 
of G’ vs. stress is shown. The yield stress or otherwise known as onset point (σY) can be determined 
from the figures as the point where the two tangents (from the linear and the non-linear portion of 
the curve) intersect. The yield stress for the extruded gel is 900 ± 80 Pa and that for the control gel 
was 1000 ± 70 Pa.   Each value represents the mean ± S.D. (n=3).   The results obtained for the 
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yield stress for the 30% extruded and the control gel indicate similar flow properties. From the 
Figures 13 and 14 C., at low shear values, the viscosity of the products is high, thereby providing 
good firmness to the products. As the shear values increase, the viscosity of the formulations 
decreases rapidly, thereby allowing the products to easily spread over a large surface area. 
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Figure 13. Rheological characterization plots of 30% extruded gel (A) modulus vs. strain 
%, (B) storage modulus vs. stress, (C) viscosity vs. shear rate. 
 
 
C. 
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Figure 14. Rheological characterization plots of 30% control gel (A) modulus vs. strain %, (B) 
storage modulus vs. stress, (C) viscosity vs. shear rate. 
 
A. B. 
C. 
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3.5. In - vitro release study 
A non-porous hydrophobic silicone membrane was selected for this study. Such 
membranes are inert and only permit the lipophilic drug to pass through, thereby separating the 
receptor media from the formulation. In doing so, the dissolution of the poloxamer into the receptor 
media can be prevented (Dumortier et al., 2006). The amount of drug released from the extruded 
gels was 40.73 ± 6ug/cm2 and from the control gels was 35.8 ± 5ug/cm2. 
 Poloxamer gels comprise of micelles and aqueous channels and it is from these aqueous 
channels that the drug is released. Some of the factors affecting drug release from the poloxamer 
gels include the viscosity of the gels, the size of aqueous channels and the dispersal of the drug in 
the micellar and aqueous regions. As poloxamer 407 forms viscous isotropic liquid crystal gels 
that mainly comprise of micelles, therefore it was likely that the drug was released by a diffusion 
mechanism via the extra micellar water channels of the gel.  
The release of KTP from the poloxamer gel gave a best fit to the Higuchi equation as from 
the plot of Q vs. √T, the release of the drug increased with increase in time (r > 0.98) (Figure 15). 
The Higuchi equation is given by  
Qt = Kh * t1/2 
where, Qt is the amount of drug released in time ‘t’ and Kh is the Higuchi diffusion rate constant 
(Gilbert et al., 1986; Ricci et al., 2005; Bentley et al., 1999; Nair and Panchagnula, 2003; Su and 
Miller, 1990; Patil et al. 2015). The rate constant calculated from the plot of Q vs. √T for the 
extruded formulation was 11.9 ± 1.7 and that for the control formulation was 11.1 ± 1.0.   Each 
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value represents the mean ± S.D. (n=3). The p-value obtained from the t-test was 0.57 for the 
formulations. As the p value obtained was greater than 0.05, therefore for the release study, the 
two formulations were not considered to be statistically significant. 
        
Figure 15. Plot of Q vs. √T for the calculation of Higuchi diffusion rate constant. 
3.6. Ex - vivo permeation study 
Several alternatives to the human skin such as rodents, monkeys, pigs, etc. are used for ex-
vivo permeation studies but porcine epidermis is preferred as it can be easily obtained and is the 
closest alternative to the human skin based on its morphological characteristics. The results of the 
ex-vivo permeation studies for the 30% poloxamer gels are shown in Figure 16. For 30% 
poloxamer gels, the amount of drug permeated from the extruded gel was 4.08 ± 1.1 µg/cm2 and 
from the control gel was 3.97 ±1.2 µg/cm2. Each value represents the mean ± S.D. (n=3). The p - 
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value obtained from the t-test for the formulations of 30% poloxamer gels was 0.90. As the p-value 
obtained was greater than 0.05 for the 30% gel formulations, therefore the two formulations were 
not statistically significant for the permeation study. Based on the results of the in-vitro release 
study and the ex-vivo permeation study, for the 30% poloxamer gels, no significant difference was 
obtained between the extruded and the conventional gels which was confirmed from the results of 
the statistical t-test conducted on the formulations. 
     
Figure 16. Cumulative amount of KTP permeated vs. time from 30% poloxamer gels. 
3.6.1 Development and ex - vivo permeation studies of 40% poloxamer gel formulations 
As the extruded and the control 30% poloxamer gel formulations had similar characteristic 
properties, therefore another set of gel formulation were developed that consisted of a higher 
concentration of poloxamer content and characteristic studies were conducted on them. During the 
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extrusion of the 40% poloxamer gels, minimum torque was maintained, and the end product was 
a clear gel formulation devoid of air bubbles. Therefore, the melt extrusion technology could be 
successfully employed to prepare 40% poloxamer gels. Ex-vivo permeation studies were 
conducted for these gels. For 40% poloxamer gels, the amount of drug permeated from the 
extruded gel was 2.8 ± 0.3 µg/cm2 and from the control gel was 1.5 ± 0.2 µg/cm2.   Each value 
represents the mean ± S.D. (n=3).  
As the concentration of poloxamer in the gel increases, the amount of drug permeated from 
the formulation decreases as can be seen from Figure 17. The gel structure behaves as a barrier to 
drug diffusion and the resistance of the drug to diffuse out of the formulation increases as the 
poloxamer concentration increases. This could be attributed to the decrease in the number and 
dimensions of the water channels with an increase in the number of micelles that occurs when the 
poloxamer concentration increases (thereby resulting in an increase in the solubility of the drug) 
(Sin et al., 1999; Chen-Chow and Frank, 1981; Moore et al, 2000). The Fickian equation explains 
the passive permeation of a permeant across the strateum corneum and is defined as the amount of 
drug entering a membrane equal to the amount of drug leaving a membrane and is given by the 
following equation – 
Jss = Kp. Cveh 
Where, Jss is the steady-state flux (ng h
-1.cm-2) across a membrane of thickness ‘h’ cm, Cveh is the 
drug concentration (mg cm-3) in the vehicle, and Kp is the formulation dependent permeability 
coefficient of the drug (Naik et al., 2000). From the permeation figures (Figures 16 and 17), the 
flux was calculated as the slope of the linear part of the curve. The flux obtained for the 30% 
extruded and the control formulations were 0.4 ± 0.1 µg h-1.cm-2 and 0.4 ± 0.1 µg h-1.cm-2 
respectively. For the 40% extruded and the control formulations, the flux values were 0.2 ± 0.01 
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µg h-1.cm-2 and 0.1 ±0.02 µg h-1.cm-2. For the 30% extruded and the control formulations, the drug 
retained in the epidermis was 4.3 ± 1.2μg of drug/mg of skin and 3.4 ± 1.1μg of drug/mg of skin 
respectively. For the 40% extruded and the control formulations, the drug retained in the epidermis 
was 3.0 ± 1.3μg of drug/mg of skin and 2.2 ± 0.56μg of drug/mg of skin. The results for flux and 
the drug retained represent the mean of three values. From these results, we observe that the drug 
retained in the epidermis decreased with increasing concentration of poloxamer, thereby relating 
well with the flux values. The p-value obtained from the t-test for the 40% poloxamer gels was 
0.02. As the p-values obtained were less than 0.05 for the 40% gel formulations, therefore the 
extruded and control 40% gel formulations were statistically significant for the permeation studies. 
         
Figure 17. Cumulative amount of KTP permeated vs. time from 40% poloxamer gels. 
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3.7. Microscopic studies 
From the results, unlike in case of 30% gel formulations, a significant difference in the 
permeation of the drug was observed between the 40% poloxamer extruded and control gels. To 
investigate the cause for the significant difference in permeation, a microscopic study was carried 
out for the formulations. The differences in performance can be due to the differences in the post 
application changes to the product. To investigate the effect of the post application changes on the 
product, microscopic studies were performed by applying the same amount of gel using an 
applicator on a slide to create a thin film. The products on the slides were observed under the 
microscope for changes. The images shown in the figures depict the gel formulations examined 
under the microscope for drug crystals at different time intervals (0, 1 and 2hr).  
 Crystallization could be induced due to the loss of significant amounts of water from the 
gel leading to concentrated or supersaturated zones causing nucleation and crystallization or due 
to complete drying of water in some of the regions on the applied area would lead to precipitation 
of drug. The presence of large amount of drug crystals (image C.) as shown in Figure 18 indicate 
that KTP crystals started appearing from the 2nd hour for the extruded gel. On the contrary, drug 
crystals started to show from the 1st hour (image D.) for the control gel as shown in Figure 18. This 
difference in the presence of the drug crystals at different times could be attributed to the difference 
in the drying rate of the gels. The extruded gel had a slower drying rate in comparison to the control 
gel. Thus, KTP stayed in the solubilized form in the extruded formulation longer than in the control 
formulation. This difference in drying rate explained why more amount of drug could permeate in 
the extruded gel as compared to the control gel. However, at this point it is not clear why HME 
processed gels are relatively superior in retaining water as compared to gel prepared by the 
conventional method. 
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Figure 18. Microscopic images of 40% extruded gel at (A) 0 hr (B) 1 hr and (C) 2 hr and   
control gel at (D) 0 hr (E) 1 hr and (F) 2 hr. 
3.8. pH measurements   
The pH of a semisolid product affects the stability and solubility of the active ingredient in 
the formulation. The pH obtained for the extruded formulations was 3.8 ± 0.07 and that for the 
control formulations was 3.9 ± 0.2. Several authors who have developed poloxamer gel 
formulations have also reported the pH of the poloxamer gels in this range (Chi and Jun, 1991; 
Shin et al., 1999; Suh and Jun, 1996).  
3.9. Uniformity of drug content  
As mentioned above, the mixing that is provided by the hot-melt extruder results in the 
drug being uniformly distributed in the polymer matrix which is one of the key factors to be taken 
A. B. C. 
D. E. F. 
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into consideration while developing gel formulations. The drug content obtained for the extruded 
formulations was 100.9 ± 0.7% and for the control formulations was 97.2 ± 5.2%. As a lower 
standard deviation was obtained for the extruded gel (0.7%) as compared to the standard deviation 
obtained for the control gel (5.23%), therefore the results from the drug content analysis indicate 
that the optimized screw configuration provided enough mixing to the formulation resulting in a 
homogenous distribution of the drug in the polymer matrix. 
4. Conclusions 
In this study, topical semisolid gels were prepared by the HME technology as well as the 
conventional technique and characteristic properties were compared between the formulations. 
The results from the in-vitro release study showed the drug release from the polymer matrix was 
governed by a diffusion process. Ex-vivo permeation studies were conducted for 30% and 40% 
poloxamer gels. It was observed that as the concentration of poloxamer increased in the 
formulation, the viscosity of the gel increased and therefore the amount of drug permeated from 
the gel decreased. A texture analysis and a rheology study were also conducted for the 30% 
poloxamer gels. The textural and the rheological values obtained were similar for the extruded and 
the control gels. In conclusion, the HME technology could be successfully used to develop 
poloxamer gels. In the development of the gel formulations, the advantages of the HME 
technology such as short processing times, cost efficient process and uniform mixing can 
overcome the disadvantages associated with the conventional methods of preparation.
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CHAPTER 3 
A QUALITY BY DESIGN APPROACH TO DEVELOP TOPICAL CREAMS VIA THE HOT-
MELT EXTRUSION TECHNOLOGY 
1. Introduction 
In comparison to topical ointments, topical cream formulations are more acceptable to 
patients as they can be effortlessly applied on all regions of the skin without imparting the greasy 
feel that is inherently present in ointments. Also, in comparison to lotions, creams are more potent 
and occlusive for longer periods of time (Grisby and Bryant, 2000). Topical creams are 
conventionally prepared by the fusion process wherein the oil phase and the water phase 
components are separately heated and mixed in jacketed vessels before being combined with 
continuous agitation to form an emulsion but prolonged processing times, expensive equipment, 
consumption of large amounts of energy and scale-up issues are some of the challenges faced 
during the fusion process (Mendonsa et al., 2018).  
The hot-melt extrusion process is a continuous process that consists of the polymers, drug 
and the other excipients being fed into the extruder and subjected to temperatures above the glass 
transition temperature of the polymers and/or over the melting temperature of the components 
while simultaneously being pushed forward towards the die by rotating screwsto obtain a 
molecular type of mixing of the components involved (Mendonsa et al., 2017). In the development 
of topical formulations, this technique has already been established to be a cost - efficient process
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(the product obtained is devoid of air bubbles and hence does not require any de-aerators or cooling 
units), as well as short processing times. In addition, the high kneading and dispersing capacities 
of the mixing elements of the extruder can provide a uniform dispersion of the drug particles in 
the molten polymer matrix (which is crucial requirement for a scale-up process) as well as prevent 
the formation of agglomerates when the oil phase and the aqueous phase components are mixed 
together. These advantages have contributed to this process being considered as a suitable 
alternative over the conventional methods of manufacturing (Mendonsa et al., 2018).  
The idea of Quality by Design (QbD) as a strategy to acquire an in depth understanding of 
the pharmaceutical manufacturing process at different stages of the initial product development 
process and the commercial cycle has been encouraged by the global regulatory agencies such as 
the United States Food and Drug Administration (US FDA) and the European Medicine Agency 
(EMA). Through this approach, one would acquire a good understanding of the product, its process 
design and further improvement, the scale-up parameters and optimize and control these steps, 
therefore improving the efficiency of the process and the quality of the product. Through the 
conventional method of Quality by Testing (QbT) approach, one would expect batch failures that 
would frequently occur with no possible cause wherein, in the quality by design approach, 
operational flexibility was possible provided the product variables and the process parameters 
remained within the approved design space (Kayrak-Talay et al., 2013; Patil et al., 2015; Patil et 
al., 2016). 
The entire body is a target for side effects (glaucoma, weight gain, high blood pressure, 
etc.) instead of a specific area when corticosteroids are administered through the oral route. When 
inhaled, corticosteroids could accumulate in the mouth and in the throat, regions causing irritation 
and fungal infections. When given through the systemic route, it can result in temporary side 
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effects such as skin thinning and insomnia. Hence corticosteroids are preferably administered 
through the topical route to avoid significant side effects. Hydrocortisone Acetate (HA), a synthetic 
corticosteroid, is utilized for cutaneous disorders such as inflammatory dermatitis and is preferred 
over other low dose corticosteroids as it possesses a fast onset of action and therefore, was selected 
as a suitable drug for this study (Fini et al., 2008).  
With the conventional methods of topical cream preparation having several disadvantages, 
the novel aim of this work was to develop topical cream formulations via the melt extrusion 
technology using a quality by design approach (using the Design of Experiment tool) to study the 
effects of the processing parameters of this technology on the characteristic properties of the final 
product. 
2.   Materials and Methods 
2.1.  Materials 
Stearic acid and potassium hydroxide were a kind gift from Acros Organics (Morris, 
USA). Stearyl alcohol (Kolliwax SA) was a gift from BASF (Ludwigshafen, Germany). Cetyl 
alcohol (Crodacol C95) was purchased from Croda Inc. (New Castle, USA). Hydrocortisone 
Acetate was a kind gift from PCCA (Houston, USA). Glycerol was purchased from Fisher 
Scientific (Bridgewater, USA). Propyl paraben was purchased from Spectrum (New Brunswick, 
USA). The other reagents used in this grade were of analytical grade. 
2.2.  Preliminary study and design of experiments 
The preliminary studies were conducted to identify the process variables that would have 
a significant impact on the characteristic properties of the cream formulations. Based on
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preliminary extrusion studies, three process variables were identified which were the temperature 
of zone 2, screw speed and screw configuration. Each of these factors were studied at two levels 
i.e. a lower and a higher level (Table 3). A factor influence study was then conducted to quantify 
their individual influence as well as to study how each factor is influenced by other factors. A 
factorial design that involves the selection of process parameters as well as response variables 
can be utilized to conduct a factor influence study in which all levels of one factor can be 
combined with all levels of other factors. Through a factorial design, one can separate the factors 
that are significant from those that are not as well as investigate the interactions between the 
selected factors, if any. Based on the process parameters selected as well as the levels considered 
for each factor, a 23 factorial design was considered for this study. The response variables 
selected were yield stress, globule size and work of adhesion (Korakianiti et al., 2000; Singh et 
al., 2005). The factorial design resulted in the extrusion of 8 cream formulations (Table 3). 
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Table 3. A. Experimental factors with their levels B. experimental design. 
 
23 Factorial 
Design 
X1 X2 X3 
1 55 70 A 
2 40 50 B 
3 40 50 A 
4 55 50 B 
5 55 70 B 
6 40 70 A 
7 40 70 B 
8 55 50 A 
  
Factor Factor significance Level (-1) Level (+1) 
X1 Temp. of zone 2 40 55 
X2 Screw speed 50 70 
X3 Screw configuration A B 
 
 
 
A. 
B. 
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2.3.  Hot - melt extrusion 
The composition of the cream formulation is shown in Table 4 (Pillai et al., 2001). 
Stearic acid, stearyl alcohol, cetyl alcohol and the drug which comprised of the oil phase were 
sieved through US# 35 mesh screen and blended using a V-shell blender (Maxiblend, Globe 
Pharma, New Brunswick, NJ). The blend was then fed to a co-rotating twin screw extruder 
through a volumetric feeder having an extrusion die of diameter 5.79 mm (Process 11, Thermo 
Fisher Scientific, Karlsruhe). Glycerol, propyl paraben, potassium hydroxide and water that 
made up the aqueous phase were pre-heated to 70℃ on a hot plate prior to feeding the mixture to 
the extruder. The pre-heated aqueous phase was then added into the extruder via an injection port 
connected to a peristaltic pump at zone 4. Figure 19 demonstrates the extrusion process carried 
out to develop the cream formulations. The flow rate of the oil phase and the water phase was set 
to 3 rpm and 4.8 ml/min respectively based on preliminary extrusion studies conducted. The 
temperature of the barrel was gradually decreased and set as follows: zone 2 – 40/55℃, zones 3-
4 - 70℃, zone 5 - 55℃, zone 6 - 50℃, zone 7 - 45℃ and zone 8 and die - 40℃. The screw 
configurations considered for the study are also illustrated in Figure 19. 
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Table 4.  Composition of the HC topical cream  
 
 
 
 
Oil Phase 
Ingredient % weight/weight 
Stearic Acid 11 
Stearyl Alcohol 0.85 
Cetyl Alcohol 0.85 
Hydrocortisone Acetate 1 
 
 
Water Phase 
Glycerol 0.8 
Propyl Paraben 0.12 
Potassium Hydroxide 0.34 
Water 85.04 
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Figure 19.  Modified screw configurations (A & B) and schematic representation of the HME 
process (C). 
A. 
B. 
C. 
56 
 
2.4.  Characterization of cream formulations 
2.4.1.    Texture analysis 
A texture analyzer with a 5 kg load cell (Model TA.XT2i, Texture Technologies Corp. 
/Stable Micro Systems) was used to conduct the textural analysis for the creams. A cylindrical 
acrylic probe having diameter of 1 in (TA-3) with a soft matter kit (TA-275) was used. The 
sample was placed onto the soft matter fixture and the cylindrical probe was attached to the arm 
of the texture analyzer. Prior to the experiment, the surface of the sample was levelled by 
swiping any extra cream formulation. The probe was brought down at a speed of 1mm/sec until 
it touched the sample surface. On touching the sample surface and detecting a trigger force of 5 
g, the probe produced a deformation of 2 mm while moving at a speed of 2 mm/sec. The probe 
was then lifted off the sample surface at a speed of 10 mm/sec. prior to the next analysis, the 
probe and the soft mater fixture were cleaned (Mendonsa et al., 2018). 
2.4.2.  Rheology analysis 
The rheological study for the formulations was conducted on a TA instrument HR-2 
rheometer. A temperature of 32℃ was set using a Peltier system. A parallel plate geometry was 
used (20 mm) with the upper and the lower plates having adhesive backed sand papers (grit 
number #600, Allied High-Tech Products) attached to them to decrease the slippage of the 
sample at the sample-rheometer plate interface. The lower plate had 400 mg of the sample 
applied onto it during which the upper plate was at a gap of 550µm. Having removed the excess 
sample, the upper plate was then set at a gap of 500 µm for the experiment. To reduce possible 
water loss during the testing, the rheometer was attached to a solvent trap. The study was 
conducted in four steps: the first step was a time sweep study for 5 minutes for the sample to 
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relax from the stress it acquired during loading (strain (γ0) of 0.1% and frequency (ω) of 1 Hz). 
The second step was the strain sweep test conducted at γ0 range of 0.05–50% with ω of 1 Hz. The 
third step was the time sweep study conducted prior to the steady shear test which comprised of 
the fourth step wherein, the shear rate was steadily increased to a maximum shear rate of 100 s-1 
in the forward mode and then steadily decreased to a minimum shear rate of 0.002 s-1 in the 
backward direction. 
2.5.  Analytical method 
A Waters high performace liquid chromatography (HPLC) UV (Waters Corp, Milford) 
system equipped with a dual λ absorbance detector with a Waters C18 (4.6 x 150 mm; 5 μm 
particles) column was employed to detect the HA content. The mobile phase comprised of 
Methanol and Water (67:33 v/v) with a set flow rate of 1 ml/min. The injection volume was set 
to 10 µl with the UV detector set to 248 nm (Pedersen et al., 2000). 
2.6.  In-vitro release study 
The in-vitro release study was performed on vertical Franz diffusion cells having an 
active diffusion area of 0.64 cm2 (Logan Instruments, Somerset). A silicone membrane (non-
porous and hydrophobic) having a thickness of 0.005 inches (Speciality Manufacturing, Inc., 
Saginaw) was a suitable membrane for the study. The cream formulation (100mg) was applied 
onto the membrane and was placed between the donor and the receptor compartments. The 
receptor compartment consisted of phosphate buffer saline solution at a pH of 7.4 (degassed 
prior to the experiment) to simulate systemic conditions and the cells were constantly stirred with 
a temperature set to 32°C (Ueda et al., 2009). 
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2.7.  Ex-vivo permeation study 
The ex-vivo permeation studies were performed on vertical Franz diffusion cells having 
diffusion area of 0.64 cm2 (Logan Instruments, Somerset). The membrane used for this study 
was a freshly slaughtered porcine epidermis which was obtained from a local abattoir and was 
kept in 8℃. It was thawed at room temperature on the day of the experiment. Cream 
formulations were uniformly applied onto the epidermis which was placed between the donor 
and receptor compartments. The receptor compartment consisted of PBS 7.4 (degassed before 
experiment). A temperature of 32℃ was set with the cells being provided with constant stirring. 
Prior to the experiment, the cells were kept for equilibrium for 1 hour. At regular time intervals 
(up to 10 hours), 0.2 ml of the sample was withdrawn and was replaced with fresh PBS of the 
same volume. The samples were then analyzed through the HPLC system (Şenyiğit et al., 2011). 
2.8.  Extraction of HC from the epidermis 
At the end of the permeation study, the epidermis was rinsed using methanol and water to 
remove the leftover formulation. The active diffusion area was then obtained using a biopsy 
punch and weighed. After adding appropriate amounts of 2N NaOH and placing it in an oven set 
to 50℃, the active epidermis was homogenized. Appropriate dilutions are made with acetonitrile 
after which it was subjected to vortex and centrifugation. The supernatant collected was then 
analyzed for drug content through the HPLC system (Maurya and Murthy, 2014). 
 
 
 
59 
 
2.9.  pH measurement 
pH of the cream formulations was evaluated through the Mettler Toledo InLab® Micro 
pH probe (Mettler Toledo, Columbus) (Chi and Jun, 1991).  
2.10. Uniformity of drug content 
Weighed amounts of the formulations were collected from three regions of the container 
and were dissolved using appropriate amounts of acetonitrile and sonicated. Samples were then 
analyzed for drug content through the HPLC system.  
2.11. Globule size measurements and stability studies 
The formulations were stored at room temperature and at conditions of 40℃/75% RH for 
time periods of 1 and 3 months. The globule size for the formulations were determined using an 
Olympus IX inverted research microscope. A uniform layer of the sample was obtained by 
applying 15mg of the creams onto a glass slide and slowly pulling the sample to form a thin layer 
with the aid of a second glass slide. This slide was then studied under the microscope with a 10X 
objective lens. The images obtained from the microscope were then analyzed using the Zen Lite 
software. The globules were manually counted and an average of 50 randomly selected globule 
diameters for each formulation were considered for the design of experiment (DOE) study. A 
size distribution curve (d10, d50, d90) at room temperature and 40℃/75% RH was plotted to 
determine the stability of the formulations.  
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2.12. Statistical data analysis 
Statistical significance between formulations were evaluated through a one-way analysis 
of variance (ANNOVA) test followed by a Tukey test. If the p-value obtained was less than 0.05, 
the formulations were considered to be significantly different. A mean of three readings were 
considered. 
3.   Results and Discussion 
3.1.  Selection of critical process parameters and critical quality attributes  
Cream formulations intended for topical use have different patient tolerance levels than 
oral or parenteral formulations. Some of the properties of cream formulations that influence the 
acceptance levels include textural profile (appearance, odor and extrudability), spreadability, 
tackiness, greasiness after application, etc. (Barry and Grace, 1972; Krishnaiah et al., 2014). 
Yield stress which is defined as the minimum amount of shear stress required to initiate 
an irreversible plastic flow in a product has been known to have a direct influence on the 
spreadability of the cream formulations. Besides the spreading properties, yield stress also affects 
the physical stability of the product. In addition, a formulation with a smaller globule size would 
indicate a higher skin permeation and physical stability (Patel et al., 2013). Hence, yield stress, 
work of adhesion and globule size were selected as the critical quality attributes (CQA)/response 
variables for this study.  
The mixing process in a twin-screw extruder is generally comprised of dispersive and 
distributive mixing. The staggering angle and the width of the disks of the mixing elements have 
an impact on the mixing processes, both of which contribute to a homogenous product. The 
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mixing process as well as the screw speed contribute to the shear produced in the extruder with a 
higher dispersive mixing and a higher screw speed contributing to a greater shear (Shibata et al., 
2009; Van Melkebeke et al., 2008). It is critical that the oil phase components be completely 
melted before the addition of the aqueous phase to avoid recrystallization of the oil phase 
ingredients (thereby resulting in a non-homogenous product), but during preliminary extrusion 
studies, it was observed that when the temperature of zone 2 was set to 70℃ (melting 
temperature of stearic acid), a molten mass at zone 2 was formed and hence the blend was unable 
to move forward. Therefore, lower temperatures of 40 and 55℃ were used instead. The screw 
configuration (modified), screw speed and the temperature of zone 2 were hence selected as 
critical process parameters (CPP) for this study. 
3.2.  Experimental design 
A two-level factorial design is the easiest form of orthogonal design that is often used for 
screening and factor influence studies.  Some of the advantages factorial designs offer include 
being efficient in determining the main effects when interactions are not present, calculated 
effects and interactions are not dependent on the effects of other factors (orthogonality) and 
conclusions can be made over a range of conditions as factor effects are determined by changing 
levels of other factors (Bolton and Bon, 2009).  
Based on the analysis of the factors on the responses, linear equations were derived for 
each of the responses and are given as: 
Y1 = 42.75 – 5 * X1 - 1.50* X2 + 4.50 *X3 (1)                                                                           
Y2 = 47.21 + 6 * X1 - 0.5824 * X2 + 2.20 * X3 (2)                                                                   
Y3 = 0.9228 – 0.223 * X1 + 0.2355 * X2 – 01673 * X3 (3)                                                                 
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Where Y1, Y2 and Y3 stand for the yield stress, work of adhesion and the globule size and X1, X2 
and X3 stand for temperature of zone 2, screw configuration and screw speed respectively. The 
first term of each equation represents the arithmetic mean of the responses of the 8 formulations. 
The purpose of these equations is to describe the effect that each factor has on the response 
variables. The magnitude (numerical value) and the direction (signs) of the factor coefficients in 
equations 1-3 describe the nature of the effect (i.e. whether the response variables would increase 
or decrease with change in process parameters). A higher value of magnitude implies a greater 
impact on the response variable. 
3.3.  Effect of temperature of zone 2 
The temperature of zone 2 was varied at two temperatures: 40 and 50℃. From Eqns. (1-
3), we observe that as the temperature was increased, work of adhesion also increased as 
indicated by the positive sign for the coefficient X1 in Eqn. (2). For both the yield stress and the 
globule size variables, a negative effect was observed Eqns. (1 and 3). Since the p-value obtained 
was less than 0.05, the effect was not only positive but significant as well (Table 5).  
Some of the key factors to consider while studying the work of adhesion for a semisolid 
formulation include its viscosity, rate and time of shear that occurs during spreading, temperature 
at the site of application, etc. (Garg et al., 2002). Yield stress is indirectly proportional to the 
work of adhesion of the product (higher the yield stress, lower would be the work of adhesion). 
A desired trend in both the yield stress and the work of adhesion was observed with increase in 
temperature of zone 2 as demonstrated in Figure 20. As mentioned earlier, it is mandatory that 
the oil phase be completely melted prior to the addition of the aqueous phase. In this study, the 
oil phase had two zones (zones 2 and 3) to melt and form a homogenous blend before the 
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addition of water at zone 4. It is possible that when the temperature was increased from 40 to 
50℃, it aided in the efficiency of mixing and melting of the oil phase ingredients therefore 
having a possible impact on the textural and the rheological properties of the cream. The effect 
of temperature on the consistency of a w/o cream was also demonstrated by Tamburic et al. 
(1996) wherein the temperature used in the preparation of the creams by the cold emulsion 
technique (in comparison to the hot emulsion technique) resulted in a favorable product.  
 
Table 5. ANNOVA table for the response variables. 
 
Source Sum Square df Mean 
Square 
F-value p-value 
prob>F 
Yield Stress (Y1) 
Model 380 3 126.6 1.7 0.2 
X1 200 1 200 2.8 0.1 
X2 18 1 18 0.2 0.6 
X3 162 1 162 2.2 0.2 
Work of adhesion (Y2) 
Model 329.2 3 109.7 4.2 0.09 
X1 287.9 1 287.9 11.1 0.02 
X2 2.7 1 2.7 0.10 0.7 
X3 38.6 1 38.6 1.4 0.2 
Globule size (Y3) 
Model 1.0 3 0.3 0.5 0.6 
X1 0.4 1 0.4 0.6 0.4 
X2 0.4 1 0.4 0.6 0.4 
X3 0.2 1 0.2 0.3 0.5 
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Figure 20. Effect of temperature of zone 2 on Work of Adhesion (WOA) (A) and  
Yield Stress (B).  
3.4. Effect of screw configuration 
Two screw configurations were used in this work: screw configuration A and screw 
configuration B. Based on Eqns. (1-3), it was noted that a positive impact was observed only on 
the globule size variable with change in screw configuration Eqn. (3) whereas a negative effect 
was observed on the yield stress and the work of adhesion variables Eqns. (1 and 2). But despite 
the positive impact, with the p-value being greater than 0.05, the effect on the globule size was 
not considered to be significant (Table 3).  
The primary difference in the two configurations was the extension of the second mixing 
zone as can be seen from Figure 19. Mixing zones are generally considered to possess low 
conveying ability, thereby extending the residence time of the blend within the extruder at which 
time the material is subjected to additional mixing which would further reduce the globule size 
A. B. 
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of the formulations.  Extension of mixing zones can give rise to high torque values but during the 
extrusion runs, a minimum torque of 3-4% was maintained in the barrel. 
3.5.  Effect of screw speed 
Two screw speeds were used in this study: 50 and 70 rpm. From Eqns. (1-3), it was 
observed that a positive impact on yield stress and work of adhesion Eqns. (1 & 2) were obtained 
on modifying the screw speed. Despite the favorable impact, as the p-value was more than 0.05, 
therefore the effects on the yield stress and the work of adhesion were considered to be 
insignificant.  
Screw speeds are associated with residence time of the physical blend in the extruder, 
wherein, when the extruder is operated at lower screw speeds, due to an increase in the residence 
time, the physical blend would experience a higher input of thermal energy in the presence of a 
low shear environment and therefore be subjected to low shearing action. Having been subjected 
to increased thermal energy, the resulting product would undergo a good expansion. On the other 
hand, high screw speeds would indicate low residence times but with an increase in the rate of 
shear (Bhattacharya, 1997). As the screw speed is gradually increased, the magnitude of torque 
decreases primarily due to the decrease in the filled length within the extruder and an increase in 
the rate of shear that would reduce the apparent viscosity of the material inside the extruder (due 
to the material behaving as a pseudo plastic material which demonstrates shear thinning behavior) 
(Guha et al., 1997; Bhattacharya et al., 1992).  
The screw speed and the screw configuration together contribute to the shearing rate which 
is graphically demonstrated in Figure 21.  Each value represents the mean ± S.D. (n=3). Herein, it 
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is observed that with increase in shear rate, the viscosity of the formulations decreases which would 
indicate ease in the spreadibility of the formulations. 
            
Figure 21. Viscosity vs. shear rate for the formulations.  
3.6.  In-vitro drug release 
The in-vitro drug release rate can demonstrate the effect of both the physical and the 
chemical parameters (solubility, particle size and concentration of the active pharmaceutical 
ingredient) together with the rheological characteristics of the dosage form (such as viscosity). 
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From Table 6, it could be observed that F7 and F5 had slightly higher values of drug release in 
comparison to the other formulations.  
The viscosity of the formulation has a direct effect on the drug release on a 
microstructural level with increase in viscosity leading to either an increase or decrease of the 
drug release from the formulation. Several authors have established that an increase in viscosity 
could have a negative impact on the drug release (Adeyeye et al., 2002; Desai and Blanchard, 
1998; Jones et al., 1999; Tas et al., 2003). Lower yield stress values have been known to 
contribute to lower drug release values as well (Desai and Blanchard, 1998; Jones et al., 1999). 
However, this theory could not be applied to formulations F5 and F7 as their yield stress values 
were like the values of the other formulations (data not shown). Moreover, the viscosity obtained 
for all the formulations were similar (data not shown).  
The drug release from the creams was fit into the zero order, first order and the Higuchi 
models. The results gave a best fit to the Higuchi model as the linear correlation coefficient value 
(R2) obtained was closer to 1 as is observed from Table 4 in comparison to the other models 
(data not shown). The Higuchi equation is given in Eqn. (4): 
Qt = Kh * t1/2 (4) 
Where, Qt stands for the amount of drug release within time‘t’ and Kh stands for the Higuchi 
diffusion rate constant (Mendonsa et al., 2018). From Figure 22 which denotes the plot of Q vs. 
√T, Kh was calculated and is represented in Table 6. The formulations were not considered to be 
statistically significant as the p-value obtained was 0.3, which was more than 0.05. Each value 
represents the mean (n=3). 
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Table 6. Amount of drug release and Kh values for formulations F1 - F8.  
 
 
 
 
 
 
 
 
 
 
 
 
  
Formulation  Amount of drug 
release (µg/cm2) 
R2 values Kh value 
F1 29.4 0.9 
 
8.3 ± 0.6 
F2 31.2 0.9 8.8 ± 0.9 
F3 27.2 0.9 6.8 ± 0.7 
F4 25.1 0.9 7.3 ± 0.6 
F5 36.2 0.9 10.3 ± 0.9 
F6 25.6 0.7 7.1 ± 0.7 
F7 48.1 0.8 15.8 ± 0.8 
F8 30.7 0.9 9.8 ± 0.02 
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Figure 22. Plot of Q vs. √T for the calculation of Higuchi diffusion rate constant.  
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3.7.   Ex-vivo permeation study 
 
Figure 23 represents the results of the ex-vivo permeation study conducted for the eight 
formulations. The steady-state flux and the drug retained in the epidermis was also calculated 
and presented in Table 7.  Each value represents the mean (n=3).   With the p-value (0.8) being 
greater than 0.05, there was no significant difference obtained in the permeation of drug from the 
formulations.  
The steady state flux could be explained through the Fickian equation which describes 
the passive permeation of a permeant through the strateum corneum as the amount of drug that 
crosses through the membrane equals to the amount of drug exiting the membrane and is given 
by the below equation    
Jss = Kp * Cveh (5) 
Where, Jss stands for the steady-state flux (ngh
-1.cm-2) over a membrane having thickness of ‘h’ 
cm, Cveh stands for the drug concentration (mg.cm
-3) and Kp stands for the drug permeability 
coefficient that is dependent on the formulation (Naik et al., 2000). From the plot of cumulative 
amount of drug permeated vs. time, the flux was calculated as the slope of the linear portion of 
the curve.  
Several factors affect the permeation of the drug through the skin such as the pH and 
viscosity of the formulation, thermodynamic activity and solubility of the drug in the vehicle, 
penetration enhancers (type and concentration), etc. Frum et al. (2008) demonstrated that 
hydrocortisone gel formulations demonstrated a lower drug flux in comparison to its aqueous 
solution primarily due to the viscous nature of the gels that prevented its flow into the follicular 
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orifices, thereby preventing a direct contact between the formulation and the skin surface and 
therefore hindering intra follicular penetration.  
The drug must first diffuse out from the vehicle for the drug permeation to take place. 
Therefore, increasing the viscosity of the formulation would not only decrease the drug release 
but would also negatively impact the permeation through the skin. Dragicevic-Curic et al. (2009) 
also reported a similar trend on the effect of viscosity of the formulations on the drug release. 
Savic et al. (2007) indicated that hydrocortisone loaded creams containing light liquid paraffin 
resulted in the lower flux and permeability coefficient values in comparison to the cream 
formulations (having oil at different polarities) due to its high rheological properties (high values 
of yield stress and storage and loss modulus).  
It has also been demonstrated that the efficiency of incorporation of the drug into the 
matrix would depend on the manufacturing conditions (such as type of equipment and mixer 
speed) and this would directly impact the drug permeation (Passerini et al., 2009). As mentioned 
above, the penetration enhancers also play a role in the drug permeation. Two penetration 
enhancers were used in the formulation – stearic acid and cetyl alcohol. In general, the 
permeation mechanism of fatty acids (stearic acid) and fatty alcohols (cetyl alcohol) is the 
disruption of intercellular lipid packing and disruption of lipids that are densely packed in the 
extracellular spaces of the stratum corneum respectively (Rossi et al., 2000; Sanna et al., 2010). 
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Figure 23. Cumulative amount of HC permeated vs. time for the creams.  
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Table 7. Amount of drug permeated, flux and drug retained in the epidermis values for 
formulations F1-F8. 
Formulation Amount of 
drug 
permeated 
(ng/cm2) 
Flux 
(ng h-1.cm-2) 
Drug retained in the 
epidermis (ng of 
drug/mg of skin) 
 
F1 
 
3413.2 ± 
336.4 
 
292.7 ± 60.7 
 
 
 
116.9 ± 31.9 
 
 
 
F2 
 
3349.9 ± 
475.6 
 
336.9 ± 773.5 
 
 
 
233.3 ± 28.7 
 
 
 
F3 
 
3413.4 ± 
565.9 
 
331.9 ± 375.9 
 
 
 
205.0 ± 43.2 
 
 
 
F4 
 
4719.9 ± 
1096.3 
 
435.5 ± 423.9 
 
 
 
186.6 ± 7.4 
 
 
 
F5 
 
4284.8 ± 
308.0 
 
360.8 ± 807.8 
 
 
 
338.2 ± 48.6 
 
 
 
F6 
 
5098.7 ± 
1081.5 
 
494.7 ± 437.1 
 
 
 
250.9 ± 5.2 
 
 
 
F7 
 
3351.7 ± 
1621.8 
286.0 ± 414.5 
 
 
222.3 ± 61.4 
 
 
F8 
 
5039.5 ± 
685.6 
457.5 ± 470.0 
 
367.0 ± 73.4 
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3.8.  pH measurements and uniformity of drug content 
The pH and the drug content of the cream formulations is listed in   Table 8. The pH 
obtained was well within the accepted range for the pH of topical semisolid products (4.0 – 8.0). 
The dispersive and the distributive mixing together contribute to the homogenous distribution of 
the drug in the molten polymer matrix which is one of the major factors to be considered during 
the development of topical semisolid products. Low values of standard deviation obtained for the 
formulations demonstrate that the process parameters selected for the melt-extrusion process 
resulted in formulations having a uniform distribution of drug in the polymer matrix. 
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Table 8. pH and drug content for the formulations F1 - F8. 
Formulation pH Drug content (%) 
F1 7.0 ± 0.1 
 
 
102.4± 3.1 
 
 
F2 6.7 ± 0.0 
 
 
100.6 ± 1.0 
F3 6.7 ± 0.1 
 
 
101.3 ± 4.7 
F4 6.8 ± 0.05 
 
 
99.6 ± 0.8 
F5 6.8 ± 0.04 
 
 
100.6 ± 1.1 
F6 6.8 ± 0.09 
 
 
102.1 ± 2.5 
F7 6.9 ± 0.09 
 
 
100.6 ± 0.5 
F8 6.0 ± 0.04 
 
 
100.8 ± 0.5 
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3.9.  Globule size measurements and stability studies 
The absence of creaming and coalescence of the internal phase along with maintaining its 
elegance with respect to its appearance, color and some other physical properties are some of the 
desired features of a pharmaceutical emulsion with reference to its physical stability. Physical 
stability is determined by studying creaming and/or coalescence that takes place over a period. 
Coalescence would result when the mean globule size would gradually increase with time. 
Viscosity is not only affected with change in process parameters but is also influenced by change 
in globule size and number as well.  
Figure 24 represents the size distribution graph of the eight formulations at room 
temperature and at storage conditions of 40℃/75%RH. To compare relative stabilities of similar 
formulations, creaming and coalescence processes must be expedited by storing the formulations 
at higher temperatures. Based on the graphs, it could be observed that at room temperature, the 
formulation F1 was relatively more stable in comparison to the other formulations and at 
40℃/75%RH conditions, formulations F2, F3 and F7 were relatively more stable than the other 
formulations. Therefore, it could be inferred that change in the processing conditions did have an 
impact on the globule size distribution of the formulations with F1 being the most stable 
formulations compared to the rest.   
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Figure 24. Size distribution graph (d10, d50, d90) at RT and 40℃/75%RH for the 
formulations. 
4.   Conclusions 
In this study, topical creams were prepared by the hot-melt extrusion technology and a 
factorial design study was employed to investigate the effect of the processing parameters on the 
product characteristics of the formulations. Of the selected process parameters, only the 
temperature of zone 2 showed a statistically significant impact on the work of adhesion of the 
creams. Although statistically insignificant, screw speed did have a positive impact on the yield 
stress and work of adhesion with the change in screw configuration showing a positive impact 
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only on the globule size. The release and the permeation profile for the formulations were similar 
with the drug release from the formulations following a diffusion-based mechanism. From the 
size distribution graph, it could be inferred that despite the change in the process parameters, 
stable cream formulations could still be obtained.  
In conclusion, with the advantages that the extrusion technology has to offer over the 
conventional techniques, this technology can be successfully utilized to develop topical creams. 
However, with the technology still being widely investigated in the field of topical semisolid 
production, an ideal way to assess using this technique would be to combine the hot-melt 
extrusion technology with a quality by design approach. Through this study, one could then 
identify the key quality attributes from a patient’s point of view, which would then translate to 
ideal product characteristics. An in-depth study would be conducted to determine how process 
parameters could be differed to consistently develop a product that would possess ideal product 
characteristics, thereby fulfilling the aim of utilizing the quality by design approach, which 
would always ensure product quality. 
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